Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME study of Zanubrutinib in healthy males
NCT04163783Phase 1Completed
- Sponsor
- BeiGene
- Start
- Mar 2017
- Primary completion
- Apr 2017
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zanubrutinib in mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), chronic lymphocytic leukemia (CLL) and 2 more, sponsored by BeiGene. Primary endpoints: Area Under Concentration-Time Curve up to 13 days, Maximum Plasma Concentration up to 13 days and 7 more. Started Mar 2017; status: completed.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)Waldenström macroglobulinemia (WM)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04163783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163783.